Leadership and advisors

Chairman of the board since 2016.

‍

Born 1964.

‍

Stefan has a Master’s degree in Engineering Physics from Chalmers University of Technology and studied Business Administration in Barcelona School of Economics. Stefan has extensive experience, leading and developing companies as a CEO, including Nevs AB, Geveko AB and Elof Hanson Group. Former Senior Executive Vice President for both Volvo Buses and Volvo Trucks, former Executive Vice President at Coor, Stefan has a strong business development background, skilled in negotiation, business planning, operations management, sales, and international business.

‍

Independent in relation to the company and major shareholders.

Board member since 2012.

‍

Born in 1980.

‍

Currently the CTO of Fluicell AB, Gavin has a PhD in Chemistry from the University of Washington, Seattle. He was Assistant Professor at Chalmers University for 4 years and has published over forty peer reviewed scientific publications, with a total citation count of over a thousand. Entrepreneur/founder of two biotech and optics companies, inventor of multiple patents and technologies, Gavin has a strong background in microfluidics, single-cell analysis and optical platform integration. Gavin has published over forty research articles.

‍

Dependent in relation to the company / Independent in relation to major shareholders.

Board member since 2015.

‍

Born 1964.

‍

Owe is Senior Group Leader at the Karolinska Institute. After completing a PhD in chemistry from Gothenburg University, he completed two years of postdoctoral studies at Stanford University.
Former Global VP of R&D at Sanofi, former President of R&D at Piramal Healthcare, entrepreneur/founder and inventor of six biotech companies, Owe has over 20 years of experience in the pharma and biotech industry. Holder of more than 75 patents, author of hundreds of research articles, he is a pioneer in the fields of single-cell biology and biophysics with several products on the global market.

‍

Dependent in relation to the company / Independent in relation to major shareholders.

Board member since 2017.

‍

Born 1972.

‍

Education at Harvard University, Stanford University and UC Berkeley.

‍

Daniel has been Professor of Chemistry and Bioengineering at the University of Washington since 2006. After graduating from Stanford University, he completed postdoctoral research at Harvard University.
Scientific Founder of multiple Life Sciences/Biomedical companies across Asia, Europe, and U.S.A Member/Chair of numerous advisory and review panels for government and industry, he is a pioneer in the field of single-cell biology with several products on the global market. Daniel has authored more than 200 scientific publications and is the inventor on over 60 issued patents.

‍

Independent in relation to the company and major shareholders.

Board member since 2017.

‍

Born in 1975.

‍

Master of Laws, University of Gothenburg.

‍

Carl is an experienced and recognized lawyer at MAQS’ Gothenburg office. He has extensive experience of commercial agreements, including ones relating to cooperation, commission, and purchasing, as well as to terms and conditions. He specializes in sports, media, and the entertainment industry in which he has worked for over ten years, in addition to being the sports director of the football club BK Häcken four years. Considering Carl’s dual legal and managerial background, has led him to assist many boards in an advisory manner, or to join them as a member or a chairman.

‍

Independent in relation to the company and major shareholders.

PhD in cardiovascular physiology and pharmacology from Gothenburg University.‍Regina is Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism at AstraZeneca and leads drug development from target discovery through clinical proof-of-concept in the areas Unmet medical need and Cardiovascular and metabolic diseases. The main focus of the research that Danielson leads is to develop new therapies that can cure disease or stop disease progression, with regenerative approaches and precision medicine as key strategies. Regina is part of the management team for several strategic research collaborations, as well as in the British Heart Foundation Center for Research Excellence (CRE) Cambridge, the Physiological Systems Domain Panel and the Medical Research Council (MRC).​​

Dr. Astrid Brodd is a licensed physician who studied at the University of Toulouse and at the Sahlgrenska Academy of the University of Gothenburg. She is a board-approved dermatologist since 1993 and started the dermatology clinic at the Carlanderska hospital in 1998.

‍

Dr. Astrid Brodd is active at Diagnostiskt Centrum Hud in Gothenburg. She has extensive clinical experience both from work in Sweden and internationally.

Dr. Göran Gannedahl is a licensed physician and Ph.D who studied at the Karolinska Institute and the University of Uppsala. He is a board-approved surgeon.

‍

Dr. Gannedahl has a vast experience of drug development in different therapeutic areas from leading positions in companies such as Novartis and AstraZeneca. He is the Chief Medical Officer at Oblique Therapeutics in Gothenburg.

Prof. Michael Olausson is a licensed physician and Ph.D who studied at the Sahlgrenska Academy of the university of Gothenburg. He is a board-certified specialist in transplantation surgery.

‍

Professor Olausson has been active as a transplantation surgeon at the Sahlgrenska Academy and Sahlgrenska University hospital since 1987. He is the founder and chairman of the Sahlgrenska Transplant Institute and is the author of more than 300 research papers and book chapters. Professor Olausson is a pioneer in the area of transplantation surgery and has introduced and conducted new innovative therapies as first in the world, first in Europe, first in Scandinavia and first in Sweden.